News und Analysen
Abiomed, Inc. Starts Its Fiscal Year on a High Note
Abiomed (NASDAQ: ABMD), a medical-device company focused on minimally invasive heart pumps, reported its fiscal first-quarter earnings on Thursday, July 27. The company's results proved yet again that
Alkermes Continues to Execute
Alkermes (NASDAQ: ALKS), a biopharmaceutical company focused on diseases of the central nervous system, released its second-quarter earnings results on Thursday, July 27. The report showed that
Align Technology Again Makes Investors Smile With a Record Second Quarter
Align Technology's (NASDAQ: ALGN) first quarter was one for the record books. On Thursday, Align announced its second-quarter results. The orthodontic-device maker reported all-time high revenue
Align Technology Again Makes Investors Smile With a Record Second Quarter
Align Technology's (NASDAQ: ALGN) first quarter was one for the record books. On Thursday, Align announced its second-quarter results. The orthodontic-device maker reported all-time high revenue
Align Technology Again Makes Investors Smile With a Record Second Quarter
Align Technology's (NASDAQ: ALGN) first quarter was one for the record books. On Thursday, Align announced its second-quarter results. The orthodontic-device maker reported all-time high revenue
Executive Changes Hit NuVasive Hard
Advances in medical science have had a dramatic impact on the quality of care that patients receive. In the area of spinal surgery, NuVasive (NASDAQ: NUVA) has made a lot of headway with its minimally
Cerner Corporation Meets Expectations in Second Quarter With Solid Recurring Revenue
Cerner Corporation (NASDAQ: CERN) got off to a solid start in 2017 with its first-quarter results. The healthcare technology giant posted both revenue and earnings at the upper end of its guidance.On
Cerner Corporation Meets Expectations in Second Quarter With Solid Recurring Revenue
Cerner Corporation (NASDAQ: CERN) got off to a solid start in 2017 with its first-quarter results. The healthcare technology giant posted both revenue and earnings at the upper end of its guidance.On
Mighty AstraZeneca Takes a Lickin' on Failed Mystic Trial
When AstraZeneca (NYSE: AZN) spurned overtures from Pfizer (NYSE: PFE) to combine in one of the biggest merger deals of all time, it told investors not to worry. It had plenty of irons in the fire
Mighty AstraZeneca Takes a Lickin' on Failed Mystic Trial
When AstraZeneca (NYSE: AZN) spurned overtures from Pfizer (NYSE: PFE) to combine in one of the biggest merger deals of all time, it told investors not to worry. It had plenty of irons in the fire
Why Tetraphase Pharmaceuticals Fell 11.7% Today
After reporting positive trial results for its lead product candidate on July 25, Tetraphase Pharmaceuticals (NASDAQ: TTPH) announced a $60 million share offering today that will dilute investors, and
Baxter International Inc.'s Revenue Growth Snoozes, but Check Out the Earnings Growth
Baxter (NYSE: BAX) kept with its trend in the second quarter of marginal revenue growth, but included a substantial improvement in spending, resulting in an increase in earnings that once again beat
Natus Medical Inc Looks to Turn Things Around
Natus Medical (NASDAQ: BABY) continued the trend from the first quarter of the year: Revenue came in substantially higher in the second quarter, due to the addition of revenue from the company's
Did the Checkpoint Inhibitor Bubble Just Burst?
Shares of Agenus (NASDAQ: AGEN), a small-cap cancer immunotherapy company, were down by almost 16% at 1:20 p.m. Thursday as a result of AstraZeneca's (NYSE: AZN) Mystic trial missing its primary
Did the Checkpoint Inhibitor Bubble Just Burst?
Shares of Agenus (NASDAQ: AGEN), a small-cap cancer immunotherapy company, were down by almost 16% at 1:20 p.m. Thursday as a result of AstraZeneca's (NYSE: AZN) Mystic trial missing its primary
Novavax, Inc.: Buy the Dip?
Novavax's (NASDAQ: NVAX) investors can't seem to catch a break. The clinical-stage vaccine maker has been down on its luck ever since it released disappointing phase 3 trial results last year for its
Corning Exceeds Expectations on Optical and Gorilla Glass Strength
Corning Incorporated (NYSE: GLW) announced second-quarter 2017 results on Wednesday morning, easily beating expectations on both the top and bottom lines, thanks to strong showings from both its
Corning Exceeds Expectations on Optical and Gorilla Glass Strength
Corning Incorporated (NYSE: GLW) announced second-quarter 2017 results on Wednesday morning, easily beating expectations on both the top and bottom lines, thanks to strong showings from both its
Exact Sciences Continues to Surprise to the Upside
Exact Sciences (NASDAQ: EXAS) reported second-quarter financial results today that exceeded industry-watchers' forecasts, continuing a string of successes that has frustrated short-sellers and caused
Gilead Sciences Has 3 Available Options, but Only 1 Makes Sense
Gilead Sciences (NASDAQ: GILD) is nearing a crossroads of sorts. In short, AbbVie's (NYSE: ABBV) eight-week pan-genotypic hepatitis C combo of glecaprevir and pibrentasvir could emerge as a
Gilead Sciences Has 3 Available Options, but Only 1 Makes Sense
Gilead Sciences (NASDAQ: GILD) is nearing a crossroads of sorts. In short, AbbVie's (NYSE: ABBV) eight-week pan-genotypic hepatitis C combo of glecaprevir and pibrentasvir could emerge as a
Gilead Sciences, Inc. Boosts Its Full-Year Outlook Thanks to Stronger-Than-Expected Hep C Sales
When Gilead Sciences, Inc. (NASDAQ: GILD) reported its first-quarter results earlier this year, everyone expected sales for the biotech's hepatitis C franchise to be way down. Those expectations were
Gilead Sciences, Inc. Boosts Its Full-Year Outlook Thanks to Stronger-Than-Expected Hep C Sales
When Gilead Sciences, Inc. (NASDAQ: GILD) reported its first-quarter results earlier this year, everyone expected sales for the biotech's hepatitis C franchise to be way down. Those expectations were
Gilead Sciences, Inc. Boosts Its Full-Year Outlook Thanks to Stronger-Than-Expected Hep C Sales
When Gilead Sciences, Inc. (NASDAQ: GILD) reported its first-quarter results earlier this year, everyone expected sales for the biotech's hepatitis C franchise to be way down. Those expectations were
Biogen Inc Wants to Be the "Fastest-Growing Large-Cap Biotech Company"
Biogen (NASDAQ: BIIB) started the biotech earnings season off with a bang, generating enough revenue for the company to have confidence to increase its revenue guidance for the year. Earnings weren't